Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Fineline Cube Apr 30, 2026
Company Medical Device

Lepu Medical Technology Receives NMPA Approval for MemoSorb Biodegradable PFO Occluder

Fineline Cube Sep 11, 2023

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Company Deals

EA Pharma and TransThera Sciences Collaborate on GI and Liver Disease Therapies

Fineline Cube Sep 11, 2023

Japan-based EA Pharma Co., Ltd and China-headquartered TransThera Sciences (Nanjing) Inc. have jointly announced the...

Company Deals

GRIT Biotechnology Secures RMB 400 Million in Series B Financing to Advance TIL Pipeline

Fineline Cube Sep 11, 2023

China-based GRIT Biotechnology has announced the completion of a Series B financing round, raising RMB...

Company Deals

Oriomics Secures Series B+ Funding to Advance Liver and Digestive Cancer Screening

Fineline Cube Sep 11, 2023

Hangzhou-based Oriomics, a specialist in cancer screening based on circulating tumor DNA (ctDNA) methylation detection,...

Company Drug

Sichuan Kelun Pharmaceutical Submits Biosimilar Cetuximab for NMPA Approval

Fineline Cube Sep 11, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech...

Company Deals

Biotyx Medical Secures Over RMB 200 Million in Series B Financing for Iron-Based Stents

Fineline Cube Sep 11, 2023

China-based Biotyx Medical (Shenzhen) Co.,Ltd, known as the world’s only developer of iron-based absorbable stents,...

Company Drug

United Laboratories’ UBT251 Receives Tacit Approval for NAFLD Clinical Study in China

Fineline Cube Sep 11, 2023

Hong Kong firm United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category...

Company Drug

Abbisko Therapeutics Receives EMA Approval for Phase III Study of Pimicotinib for TGCT

Fineline Cube Sep 11, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...

Company Drug

AriBio Files for Phase III Clinical Trial Approval in China for Alzheimer’s Drug AR1001

Fineline Cube Sep 11, 2023

South Korean clinical-stage biotech AriBio Co. has announced the filing for Phase III clinical trial...

Company Drug

Allist Pharmaceuticals and ArriVent Biopharma Release Promising Interim Data on Furmonertinib for NSCLC

Fineline Cube Sep 11, 2023

Shanghai-based biotech Allist Pharmaceuticals Co., Ltd and its US partner ArriVent Biopharma Inc. have jointly...

Company Deals

iotaSciences Partners with Quantum Design China for Single-Cell Handling Platform Distribution

Fineline Cube Sep 11, 2023

UK-based cell-line engineering firm iotaSciences has announced an exclusive partnership with Quantum Design China, a...

Company Drug

BMS Announces Positive Outcomes for BMS-986278 in Progressive Pulmonary Fibrosis Study

Fineline Cube Sep 11, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has released the final results from a Phase II trial...

Company Deals

Eurofarma Invests in Abcuro as Part of $100 Million Disruptive Startups and Biotech Initiative

Fineline Cube Sep 11, 2023

Brazil-based multinational company (MNC) Eurofarma has announced an investment in US immunotherapy developer Abcuro as...

Company Drug

EMA Reviews Janssen’s Balversa for Advanced Urothelial Carcinoma with FGFR3 Alterations

Fineline Cube Sep 11, 2023

The European Medicines Agency (EMA) has accepted for review a filing made by the Janssen...

Company Drug

United Laboratories Receives Tacit Approval for JAK1 Inhibitor TUL01101 Clinical Trial

Fineline Cube Sep 11, 2023

Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced tacit clinical trial approval...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Phase Ib/III Study of Dalpiciclib in mHSPC

Fineline Cube Sep 11, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval...

Company Deals

Otsuka and Shape Therapeutics Partner on Ophthalmology Gene Therapies Development

Fineline Cube Sep 11, 2023

Japan drug maker Otsuka (OTCMKTS: OTSKY) and US firm Shape Therapeutics have announced a strategic...

Company Drug

Roche and Alnylam’s Zilebesiran Achieves Primary Endpoint in Hypertension Phase II Trial

Fineline Cube Sep 8, 2023

Roche (SWX: ROG) and Alnylam (NASDAQ: ALNY) have announced that a Phase II trial for...

Policy / Regulatory

CDE Annual Report: Clinical Trials for Innovative Drugs in China Reach Record High

Fineline Cube Sep 8, 2023

The Center for Drug Evaluation (CDE) has released its annual report on clinical trials in...

Company Drug

Pfizer and Valneva’s Lyme Disease Vaccine VLA15 Shows Promise as Booster in Pediatric Trials

Fineline Cube Sep 8, 2023

Partners Pfizer (NYSE: PFE) and Valneva SE (NASDAQ: VALN) have revealed that their Lyme disease...

Posts pagination

1 … 469 470 471 … 660

Recent updates

  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
  • Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
  • Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam
  • AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.